Tumbarello M, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54(10):4085–91.
Kanoksil M, et al. Epidemiology, microbiology and mortality associated with community-acquired bacteremia in northeast Thailand: a multicenter surveillance study. PLoS One. 2013;8(1):e54714.
Kollef MH, et al. Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect. 2011;62(2):130–5.
Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):417–32.
Sogaard M, et al. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis. 2011;52(1):61–9.
Valles J, et al. Evolution over a 15-year period of clinical characteristics and outcomes of critically ill patients with community-acquired bacteremia. Crit Care Med. 2013;41(1):76–83.
Valles J, et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123(5):1615–24.
Friedman ND, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791–7.
Siegman-Igra Y, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis. 2002;34(11):1431–9.
Deen J, et al. Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis. 2012;12(6):480–7.
(CLSI), C.L.S.I. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement ed, CLSI document M100S-S22. Wayne: CLSI; 2012.
(CLSI), C.L.S.I. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement, CLSI document M100S-S22. Wayne: CLSI; 2013.
(CLSI), C.L.S.I. Performance standards for antimicrobial susceptibility testing: 20th informational supplement, CLSI document M100S-S22. Wayne: CLSI; 2010.
(CLSI), C.L.S.I. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement ed, CLSI document M100-S14. Wayne: CLSI; 2004.
Pillar CM, et al. Prevalence of multidrug-resistant, methicillin-resistant staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER surveillance programs. Diagn Microbiol Infect Dis. 2008;60(2):221–4.
Cohen AL, et al. Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC Position paper. Infect Control Hosp Epidemiol. 2008;29(10):901–13.
Critchley IA, et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother. 2003;51(3):639–49.
Kallen AJ, et al. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol. 2010;31(5):528–31.
O’Fallon E, Gautam S, D’Agata EM. Colonization with multidrug-resistant gram-negative bacteria: prolonged duration and frequent cocolonization. Clin Infect Dis. 2009;48(10):1375–81.
Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45(9):1179–81.
Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55(Pt 12):1619–29.
Ahmed D, et al. Salmonella enterica serovar typhi strain producing extended-spectrum beta-lactamases in Dhaka, Bangladesh. J Med Microbiol. 2012;61(Pt 7):1032–3.
Brooks WA, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005;11(2):326–9.
Naheed A, et al. Burden of typhoid and paratyphoid fever in a densely populated urban community, Dhaka, Bangladesh. Int J Infect Dis. 2010;14 Suppl 3:e93–9.
Saha SK, et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J. 2001;20(5):521–4.
Rahman M, Ahmad A, Shoma S. Decline in epidemic of multidrug resistant Salmonella typhi is not associated with increased incidence of antibiotic-susceptible strain in Bangladesh. Epidemiol Infect. 2002;129(1):29–34.
Threlfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg Infect Dis. 2001;7(3):448–50.
Hassing RJ, et al. Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi a isolates from travellers to southeast Asia. Int J Antimicrob Agents. 2011;37(3):240–3.
Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002;8(11):687–93.
Cross A, et al. Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Rev Infect Dis. 1983;5 Suppl 5:S837–45.
Akram F, et al. Prevalence, clinical features, and outcome of pseudomonas bacteremia in under-five diarrheal children in bangladesh. ISRN Microbiol. 2014;2014:469758.
Brauers J, et al. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect. 2005;11(1):24–30.
Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692–9.
Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291–304.
Zavascki AP, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206–15.
Talukdar PK, et al. Antimicrobial resistance, virulence factors and genetic diversity of Escherichia coli isolates from household water supply in Dhaka, Bangladesh. PLoS One. 2013;8(4):e61090.
Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012;10(4):266–78.
Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5:S344–9.
Williams BG, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25–32.
Baqui AH, et al. Causes of childhood deaths in Bangladesh: an update. Acta Paediatr. 2001;90(6):682–90.
Brooks WA, et al. Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. Lancet. 2005;366(9490):999–1004.
Farha T, Thomson AH. The burden of pneumonia in children in the developed world. Paediatr Respir Rev. 2005;6(2):76–82.
Mamishi S, et al. Penicillin-resistant trend of Streptococcus pneumoniae in Asia: a systematic review. Iran J Microbiol. 2014;6(4):198–210.
Brooks WA, et al. Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am J Trop Med Hyg. 2007;77(5):795–801.
Klevens RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15):1763–71.
Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629–41.
Rasmussen RV, et al. Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol. 2011;6(1):43–56.